Company news

BioArctic AB news in 2025

BioArctic AB's news releases, calls and decks from 2025, newest first.

View company

Leqembi included in China's commercial insurance innovative drug list

December 8, 2025

Interim Report for the period July - September 2025: BioArctic

November 13, 2025

Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET

November 4, 2025

Sales of Leqembi® totaled 18 billion yen in the third quarter 2025

October 30, 2025

Health Canada Grants Authorization for Leqembi® (lecanemab)

October 26, 2025

First patient treated with Leqembi® (lecanemab) in the Nordics

October 14, 2025

Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.

October 6, 2025

Leqembi® approved for IV maintenance treatment in China

September 29, 2025

Leqembi® approved for the treatment of early Alzheimer's disease in Australia

September 24, 2025

BioArctic's founders intend to divest minor part of their shareholding

September 3, 2025

Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status

September 2, 2025

US FDA approves Leqembi® IQKLIK™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer's disease

August 29, 2025

BioArctic: Interim Report for the period April - June 2025

August 28, 2025

BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties

August 26, 2025

Leqembi® (lecanemab) launched in the EU today

August 25, 2025

Invitation to presentation of BioArctic's second quarter report for April - June 2025 on August 28 at 9.30 a.m. CET

August 21, 2025

Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025

July 31, 2025

The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association

July 16, 2025

BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize

June 26, 2025

BioArctic's Capital Markets Day 2025 - entering a new era of growth

June 2, 2025

Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 - March 2026)

May 15, 2025

Calls in 2025

Decks in 2025